This ‘optimal use’ project from the Canadian Agency for Drugs and Technologies in Health assesses the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The report was produced by an expert panel who based their recommendations on a systematic review and [read the full story…]
Patients with first episode psychosis often relapse after initial remission, so it is perhaps surprising that treatment guidelines for the condition are generally based on poor quality evidence. Antipsychotic drugs are frequently discontinued, but clinicians don’t have ready access to information that shows how to determine which patients can be successfully tapered off of antipsychotic [read the full story…]
This systematic literature review and meta-analysis conducted by researchers from the University of Nebraska Medical Center, will be of interest to all clinicians who treat paediatric bipolar disorder. Treatment decisions for young people have previously been based on extrapolation from adult trials, case reports, open label trials or expert opinion. This new study provides a [read the full story…]
This systematic review set out to look at the efficacy of atypical antipsychotic medication, also known as second generation antipsychotics, commonly used in the treatment of schizophrenia. There continues to be debate around whether these second-generation medications are safer or more effective than typical antipsychotics as they still can produce severe side effects. Other posts [read the full story…]
People with generalised anxiety disorder (GAD) often fail to achieve remission (recovering fully from their disease) despite standard treatments. This systematic review examines the efficacy and tolerability of second-generation antipsychotics (SGAs) for generalised anxiety disorder as either: augmentation therapy, i.e. using it alongside other treatments monotherapy, i.e. using it as a stand-alone treatment The reviewers [read the full story…]
Aripiprazole (brand names Abilify and Aripiprex) is an atypical antipsychotic drug used to treat a number of mental health disorders including schizophrenia, depression and bipolar disorder. This new guidance has been written by a group of Pan-European experts who have come together to review new clinical guidelines for the management of mania and the role of aripiprazole [read the full story…]
Antipsychotics are frequently used in the treatment of people with learning disabilities, but little is published in the literature concerning their metabolic and endocrine side-effects. The researchers in this observational study set out to compare indices of obesity, glucose, lipids and prolactin between 138 people with learning disabilities who were treated with antipsychotic medications and [read the full story…]
Around 1% of the population have autism. There are a number of treatments available for the condition, including learning and development techniques, as well as medical interventions. However, there is little consensus about which drug treatments are most effective. A team of researchers from Nashville have recently published two systematic reviews in the Pediatrics journal, [read the full story…]
We know that many people who take antipsychotic drugs find it difficult to cope with the side effects of the medication and this often leads to them stopping their treatment. This large Finish cohort study examines the risks of rehospitalisation and drug discontinuation in patients recently diagnosed with schizophrenia who have been prescribed antipsychotics. The [read the full story…]
First generation typical antipsychotics (e.g. chlorpromazine and haloperidol) have historically been used a great deal to treat people with schizophrenia. More recently, second-generation atypical antipsychotics (e.g. risperidone and olanzapine) have been more frequently used. For many, these drug therapies help to reduce psychotic episodes and the overall impact of the illness, but not all patients [read the full story…]
